study of a large, contemporary national database of a general US population aimed to evaluate national practice patterns and outcomes of unresected nonmetastatic GC receiving CT alone versus CRT. Although challenging to assess with single- or multi
Search Results
Chemoradiotherapy Versus Chemotherapy Alone for Unresected Nonmetastatic Gallbladder Cancer: National Practice Patterns and Outcomes
Vivek Verma, Swati M. Surkar, Eric D. Brooks, Charles B. Simone II, and Chi Lin
Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer
Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortes, Scott Ramsey, Andrew Briggs, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, and Peter A. Fasching
These entities stipulate 2 criteria to establish surrogacy: (1) good correlation between the surrogate endpoint and the final outcome (individual-level association) and (2) good correlation between the treatment effect on the surrogate endpoint and the
Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response
Margaret M. Kozak, Clare E. Jacobson, Rie von Eyben, Erqi L. Pollom, Melinda Telli, and Kathleen C. Horst
, patients who still had residual disease in the breast did not have better outcomes compared with those who remained LN-positive. Cumulative incidence of LF, RF, and DF at 10 years by response to NAC is depicted in Table 2 , with corresponding cumulative
Outcome Assessments and Cost Avoidance of an Oral Chemotherapy Management Clinic
Siu-Fun Wong, Mark Bounthavong, Cham P. Nguyen, and Timothy Chen
provide the convenience for self-medication at home; however, they increase the risks for nonadherence, drug interactions, and adverse drug events (ADEs), which may threaten therapeutic outcomes and patient safety. 2 Oral chemotherapy drugs are perceived
NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non–Small Cell Lung Cancer
Matthew A. Gubens and Marianne Davies
to have much poorer outcomes with single-agent immunotherapy. PD-L1 Expression ≥50% In KEYNOTE-024, pembrolizumab more than doubled median overall survival (mOS) compared with chemotherapy for patients with PD-L1 expression ≥50%, improving mOS to 30
Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes
Tiffany Li, Hannah C. Timmins, Terry Trinh, David Mizrahi, Michelle Harrison, Lisa G. Horvath, Peter Grimison, Michael Friedlander, Matthew C. Kiernan, Madeleine T. King, Claudia Rutherford, David Goldstein, and Susanna B. Park
, evaluating CIPN with a valid, reliable, and responsive outcome measure is critical in identifying early signs of nerve damage and effects of intervention aimed at preventing long-lasting or severe neurotoxicity. There are numerous approaches to assessing
Impact of the First Generation of Children’s Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor
Jeffrey S. Dome, Elizabeth A. Mullen, David B. Dix, Eric J. Gratias, Peter F. Ehrlich, Najat C. Daw, James I. Geller, Murali Chintagumpala, Geetika Khanna, John A. Kalapurakal, Lindsay A. Renfro, Elizabeth J. Perlman, Paul E. Grundy, and Conrad V. Fernandez
lack of lymph node sampling. AREN0532 demonstrated an excellent outcome with a high salvage rate for patients with disease relapse using a standardized regimen (DD4A; doxorubicin/vincristine/dactinomycin) and radiation therapy (RT) ( Table 2 ). 8 A
Baseline Hemoglobin-A1c Impacts Clinical Outcomes in Patients With Pancreatic Cancer
Katherine Y. Fan, Avani S. Dholakia, Aaron T. Wild, Zheng Su, Amy Hacker-Prietz, Rachit Kumar, Mary Hodgin, Charles C. Hsu, Dung T. Le, Ana De Jesus-Acosta, Luis A. Diaz Jr, Daniel A. Laheru, Ralph H. Hruban, Elliot K. Fishman, Todd D. Brown, Timothy M. Pawlik, Christopher L. Wolfgang, Phuoc T. Tran, and Joseph M. Herman
outcomes of hospitalized patients with cancer in terms of infection, mortality, length of stay, and toxicities. The risk of cancer death (from stomach, liver, lung cancers) has been noted to be significantly higher among those with a high fasting plasma
Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer
Zachary Veitch, Omar F. Khan, Derek Tilley, Domen Ribnikar, Xanthoula Kostaras, Karen King, Patricia Tang, and Sasha Lupichuk
-targeted therapies, such as trastuzumab. 3 – 5 However, outcomes for patients with HER2+ breast cancer treated outside of clinical trials are limited. 6 , 7 In small, node-negative, HER2+ tumors, the benefit of adding trastuzumab to adjuvant chemotherapy
Impact of Surgical Resection on Survival Outcomes After Chemoradiotherapy in Anal Adenocarcinoma
Richard Li, Ashwin Shinde, Marwan Fakih, Stephen Sentovich, Kurt Melstrom, Rebecca Nelson, Scott Glaser, Yi-Jen Chen, Karyn Goodman, and Arya Amini
data addressing management of this rare malignancy, we used the National Cancer Database (NCDB) to assess survival outcomes according to stage and treatment strategy in patients with anal adenocarcinoma. We focused our investigation on a comparison of
